Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate l-DOPA-induced dyskinesia

►Increased d-aspartate results in the loss of corticostriatal synaptic depotentiation. ►Preexisting hyper-glutamatergic tone facilitates the onset of LID. ►l-DOPA-treated Ddo−/− lesioned mice show synaptic changes in striatal NMDAR subunits.